ReviewAnatolian journal of cardiology2018
Efficacy and safety of oral anticoagulation in elderly patients with atrial fibrillation.
Review in Anatolian journal of cardiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 37 citations in OpenAlex.
- Benefit-Risk Assessment of Rivaroxaban in Older Patients With Nonvalvular Atrial Fibrillation or Venous Thromboembolism.Drugs & aging · 2025Trial
- Single-Dose Pharmacokinetics of Milvexian in Participants with Normal Renal Function and Participants with Moderate or Severe Renal Impairment.Clinical pharmacokinetics · 2022Trial
- Safety, pharmacokinetics, and pharmacodynamics of milvexian in healthy Japanese participants.Scientific reports · 2022Trial
- First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor.Clinical and translational science · 2022Trial
- Article
- Predicting venous thromboembolism and determining appropriate prophylaxis in elderly patients undergoing colorectal cancer surgery with Enhanced Recovery After Surgery (ERAS) using the adjusted Caprini score.Annals of coloproctology · 2025Article
- Hematologic Indices and Chronic Subdural Hematoma: A Single-Center Cohort Study.Asian journal of neurosurgery · 2024Article
- The Use of Oral Anticoagulation Is Not Independently Associated with Mortality in Frail Older Patients with Repeated Falls.Journal of clinical medicine · 2023Article
- Article
- Physiologically-based pharmacokinetic modeling to predict drug-drug interactions of dabigatran etexilate and rivaroxaban in the Chinese older adults.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2023Article
- Safety and Efficacy of Carbon-Ion Radiotherapy for Elderly Patients with High-Risk Prostate Cancer.Cancers · 2022Article
- Adherence and Persistence with Once-Daily vs Twice-Daily Direct Oral Anticoagulants Among Patients with Atrial Fibrillation: Real-World Analyses from the Netherlands, Italy and Germany.Drugs - real world outcomes · 2022Article
- Two-year outcomes of more than 30 000 elderly patients with atrial fibrillation: results from the All Nippon AF In the Elderly (ANAFIE) Registry.European heart journal. Quality of care & clinical outcomes · 2022Observational
- Access Site Bleeding Complications with NOACs versus VKAs in Patients with Atrial Fibrillation Undergoing Cardiac Implantable Device Intervention.Journal of clinical medicine · 2022Article
- Falls in ED patients: do elderly patients on direct oral anticoagulants bleed less than those on vitamin K antagonists?Scandinavian journal of trauma, resuscitation and emergency medicine · 2021Article
- Comparison of fibrin sealants in peripheral vascular surgery: A systematic review and network meta-analysis.Annals of medicine and surgery (2012) · 2021Review
- Impact of sex differences on outcomes in patients with non-valvular atrial fibrillation undergoing left atrial appendage closure: A single-center experience.International journal of medical sciences · 2021Article
- Non-vitamin K antagonist oral anticoagulants (NOACs) in cancer patients with atrial fibrillation.Anatolian journal of cardiology · 2020Review
- Management of patients with stroke treated with direct oral anticoagulants.Journal of neurology · 2018Review
- Atrial fibrillation and percutaneous coronary intervention: Are newer antithrombotic agents better for older patients?Anatolian journal of cardiology · 2018Article
Corrections and comments
- Commented on by
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Elderly patients with atrial fibrillation are at a higher risk of both ischemic and bleeding events compared with younger patients; therefore, balancing risks and benefits of antithrombotic strategies in this population is crucial. Recent studies have shown that because the risk of stroke increases with age more than the risk of bleeding, the absolute benefit of oral anticoagulation is the highest in elderly patients in whom it outweighs the risk of bleeding. Direct oral anticoagulants (DOACs) have been developed as a treatment for the prevention of cardioembolic stroke to overcome some limitations of warfarin, such as the need for frequent monitoring, labile INR values requiring frequent dose adjustment, dietary and drugs interactions, and increased risk of intracranial bleeding. Despite the better safety profiles of DOACs compared with warfarin, elderly patients often remain undertreated because of the fear of bleeding complications. This review summarizes current evidence regarding the risks of thromboembolisms and bleeding in different antithrombotic strategies in elderly patients (aged ≥75 years) with atrial fibrillation, including data from the warfarin-controlled phase 3 DOACs trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.